Uploaded August 2025 | Updated September 2026, 2 hours ago
Every aspect of drug development is being accelerated by AI, and pharma companies are likely to be spending over $4bn every year on AI by 2027. Comment after my AI Pharma keynote at NextGen Biomed 2025 event by Oxford Biomed.
oxfordglobal.com/nextgen-biomed/events/nextgen-biomed/look-back
AI is already being widely used to discover new drugs, which could drive up to $50bn a year of future sales. The number of new drugs developed using AI has already increased ten times in a single year, as shown in recent licence applications in the US. For example, AI is being used to:
◆ Identify potentially useful molecules for tests
◆ Design and build completely new molecules to fit cell receptors, etc.
◆ Automate testing of hundreds of molecules
◆ Streamline clinical trials
◆ Analyse data
◆ Write up results
Morgan Stanley has calculated that every 2.5% improvement in preclinical development success rates could lead to an additional thirty new drug approvals over ten years.
Key to all this is collaboration across disciplines, to drive the next phase of innovation.
Every aspect of drug development is being accelerated by AI, and pharma companies are likely to be spending over $4bn every year on AI by 2027. Comment after my AI Pharma keynote at NextGen Biomed 2025 event by Oxford Biomed.
oxfordglobal.com/nextgen-biomed/events/nextgen-biomed/look-back
AI is already being widely used to discover new drugs, which could drive up to $50bn a year of future sales. The number of new drugs developed using AI has already increased ten times in a single year, as shown in recent licence applications in the US. For example, AI is being used to:
◆ Identify potentially useful molecules for tests
◆ Design and build completely new molecules to fit cell receptors, etc.
◆ Automate testing of hundreds of molecules
◆ Streamline clinical trials
◆ Analyse data
◆ Write up results
Morgan Stanley has calculated that every 2.5% improvement in preclinical development success rates could lead to an additional thirty new drug approvals over ten years.
Key to all this is collaboration across disciplines, to drive the next phase of innovation.
